TLPH
Drug Manufacturers - Specialty & Generic · Healthcare
Equibles does not estimate personal net worth.
Get an email with a short summary when Talphera, Inc. publishes a filing, an earnings call transcript or a press release.
Get TLPH alertsTalphera, Inc. reported in an 8-K filed August 14, 2024 that Shakil Aslam was appointed Chief Development Officer, effective May 20, 2024. Talphera, Inc. reported in an 8-K filed August 14, 2024 that Shakil Aslam was appointed Chief Medical Officer. The proxy statement of Talphera, Inc. reports total compensation of $654,840 for Shakil Aslam in fiscal 2025, including a base salary of $473,200. Disclosed compensation is on record for 2 fiscal years. Shakil Aslam has spoken on 3 earnings calls across 1 company, most recently for Talphera, Inc. on November 12, 2026. Talphera, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Talphera, Inc. includes Vincent J. Angotti (CEO and Board Member), Raffi Asadorian (CFO), Abhinav Jain (Board Member) and 7 others.
“Dr. Shakil Aslam joined Talphera effective May 20, 2024 as Chief Development Officer.”
“Upon Dr. Palmer's retirement, Dr. Shakil Aslam, currently the Company's Chief Development Officer, will assume the position of the Company's Chief Medical Officer.”
“Sure, so... So there have been at least three studies attempted in this space, and those are all based on citrate regional anticoagulant. There was one study started by Vantiv that spun off from Baxter, and that started in around 2016.”
“I am very pleased with the progress we are seeing in the NephroCRRT study as we move toward completing enrollment later this year. We have completed the realignment of sites to match our target profile.”
“So, when we talk to the PIs and the investigators and then as well as the nurses who are running this study and who are doing testing and looking at some of the test results.”
Proxy statement
Start not stated–present
Last confirmed April 29, 2026
TLPH
Drug Manufacturers - Specialty & Generic · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Talphera, Inc. (TLPH) | Chief Medical Officer | $473,200 | $654,840 |
| 2024 | Talphera, Inc. (TLPH) | Chief Medical Officer | $281,215 | $529,242 |